Aytu BioPharma shares rise 14.85% premarket after strategic realignment and EXXUA launch set for Q4 2025.

Aytu BioPharma surged 14.85% in premarket trading following the release of a corporate presentation outlining its strategic realignment and the impending launch of EXXUA, a first-in-class treatment for major depressive disorder (MDD). The presentation highlighted a $34.7 million adjusted EBITDA improvement over four years, successful divestiture of its Consumer Health business, and a $22 billion US MDD market opportunity. EXXUA, with a novel 5HT1A partial agonist mechanism and patent protection through 2030, is positioned for a Q4 2025 launch, offering a premium pricing profile and differentiation from existing antidepressants. These developments underscore the company’s pivot to a profitable prescription pharmaceutical business, boosting investor confidence in its growth trajectory.